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Abstract 
Bone morphogenetic proteins (BMPs) - expressed in the developing retina – a r e   k n o w n   t o   b e  
involved in the regulation of cell proliferation and apoptosis in several tumor entities. The 
o b j e c t i v e   o f   t h i s   s t u d y   w a s   t o   d e t e r m i n e   t h e   r o l e   o f   t h e   B M P 4   p a t h w a y   i n   r e t i n o b l a s t o m a   c e l l s ,  
which are absent in a functional retinoblastoma (RB1)   g e n e . B M P   r e c e p t o r s   w e r e   d e t e c t e d   i n  
all retinoblastoma cell lines investigated. A correct transmission of BMP signaling via the 
Smad1/5/8 pathway could be demonstrated in WERI-Rb1 retinoblastoma cells and application 
of recombinant human BMP4 resulted in an increase in apoptosis, whic h   t o   a   l a r g e   e x t e n d   i s  
caspase independent. Cell proliferation was not affected by BMP4 signaling, although the 
pRb-related proteins p107 and p130, contributing to the regulation of the same genes, are still 
expressed. WERI-Rb1 cells exhibit elevated endog e n o u s   l e v e l s   o f   p 2 1
CIP1 and p53, but we did 
n o t   d e t e c t   a n y   i n c r e a s e   i n   p 5 3 ,   p 2 1
CIP1or  p27
KIP1 expression levels. Id proteins became, 
however,  strongly  up-regulated  upon  exogenous  BMP4  treatment.  Thus,  RB1  loss  in 
WERI-R b 1   c e l l s   i s   o b v i o u s l y   n o t   c o m p e n s a t e d   f o r   b y   p R b -independent (e.g. p53-dependent) 
cell  cycle  control  mechanisms,  preventing  an  anti-proliferative response to BMP4, which 
normally induces cell cycle arrest. 
Key words: retinoblastoma; apoptosis; proliferation; cell culture; bone morphogenetic protein  
Introduction 
The  expanding  transforming  growth  factor-ß 
(TGF-ß)  superfamily  includes  three  main  members: 
the TGF-ßs, the activins, and the bone morphogenetic 
proteins (BMPs) [1-3 ] .   M e m b e r s   o f   t h e   T G F -ß super-
family bind to two different types of serine/threonine 
kinase receptors termed type I and II receptors [1,2] 
a n d   a r e   k n o w n   t o   p l a y   m u l t i p l e   r o l e s   d u r i n g   n e r v o u s  
system development including stimulation or inhibi-
tion of cell proliferation, triggering programmed cell 
death (PCD), and promoting neuronal survival [4-10]. 
B M P s   a r e   w i d e l y   e x p r e s s e d   i n   t h e   e m b r y o n i c   n e r v o u s  
system including the developing retina [11-14]. 
BMP  activity  has  been  associated  with  deve-
l o p m e n t a l   P C D   i n   g e n e r a l   [ 1 5 , 1 6 ]   a n d   w i t h   a p o p t o s i s  
in  the  prospecti v e   n e u r a l   c r e s t   i n   p a r t i c u l a r   [ 1 7 ] .  
Trousse  et  al.  demonstrated  that  BMP4  mediates 
apoptotic cell death in early chick retinal development 
[ 1 1 ]   a n d   r e c e n t l y   w e   s h o w e d   t h a t   B M P 4   t r i g g e r s   g a n-
glion cell death in the developing murine retina [18]. 
BMPs  includi n g   B M P 4   h a v e   b e e n   s h o w n   t o   i n d u c e  
a p o p t o s i s   i . e .   i n   h u m a n   m y e l o m a   c e l l s   [ 1 9 -21]. Over-
e x p r e s s i o n   o f   B M P 4   h a s   b e e n   r e p o r t e d   f o r   m e l a n o m a ,  
hepatocellular carcinoma, adenocarcinoma and colo-
rectal cancer cell lines and is frequently accompanied 
by an enhanced migratory and invasive potential of 
the  tumors  [22-25].  Loss  of  TGF-ß  receptors  (TßRs) 
which normally induce growth inhibition and hypo-
phosphorylation of the retinoblastoma gene product 
Rb  represent  one  mechanism  through  which  retinal 
progenitor cells escap e   f r o m   c o n t r o l   a n d   f o r m   r e t i-Int. J. Biol. Sci. 2010, 6 
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noblastomas [26-2 8 ] .   T h e   i n a c t i v a t i o n   o f   B M P   s i g n a l-
i n g   v i a   m u t a t i o n   o f   t h e   B M P R -IA causes familial ju-
venile polyposis, an inherited gastrointestinal cancer 
predisposition syndrome [29] Some human myeloma 
cell  lines  likewise  lack  BMPR-IA  and  BMPR-IB  [30]. 
On the other hand, a significant increase in BMPR-IB 
l e v e l s   w a s   f o u n d   i n   m a l i g n a n t   h u m a n   g l i o m a   c e l l s  
[31].  
K e y   p r o t e i n s   i n   t h e   B M P   s i g n a l i n g   c a s c a d e   a r e  
Smad  and  Id  (inhibitor  of  differentiation)  proteins. 
BMPRI  activates  the  R-Smads  Smad1,  Smad5,  and 
S m a d 8 ,   w h i c h   b i n d   t o   C o -Smads and translocate into 
the  nucleus  [32,33].  The  inhibitory  I-Smads  Smad6 
and Smad7 block the activation of R- and Co-Smads 
by  TGF-ß   a n d   B M P s   [ 3 4 ] .   I n   s o m e   c e l l   l i n e s ,   w h i c h  
turned  out  to  be  resistent  to  TGF-ß  signaling,  an 
overexpression of Smad 7 has been detected [35]. 
Via the Smad pathway BMP normally activates 
p21, a CDK (cyklin dependent kinase) inhibitor pro-
tein. P21 is able to hypophosphorylate and therefore 
activate  the  Rb1  tumor  suppressor  protein,  which 
causes cell cycle arrest [36,37]. In retinoblastoma cell 
lines,  however,  the  Rb  gene  is  either  deleted  or 
non-functional. Thus, these cells might differ in their 
response to BMP4. 
Id proteins are induced in response to the Smads 
[38].  These  proteins  inhibit  bHLH  (basic  he-
lix-loop-h e l i x )   t r a n s c r i p t i o n   f a c t o r s   l i k e   E 2 A   b y  
forming  heterodimeric  complexes  and  consequently 
promote cell cycle progress [39] Furthermore, Id pro-
teins induce apoptosis or function as survival factors, 
depending on the cell context [40]. The effect of BMP4 
o n   e x p r e s s i o n   o f   I d   p r o t e i n s   i n   r e t i n o b l a s t o m a   c e l l s ,  
however, has not yet been investigated.  
Despite the tremendous progress in delineating 
functional derangements of BMP pathways in carci-
nogenesis during the last decade, the biological signi-
f i c a n c e   o f   B M P s   i n   h u m a n   r e t i n o b l a s t o m a   h a s   r e-
ceived little if any attention.  
I n   t h e   p r e s e n t   s t u d y ,   w e   i n v e s t i g a t e d   t h e   e x-
p r e s s i o n   p r o f i l e s   o f   e n d o g e n o u s   B M P 4   a n d   B M P   r e-
ceptors  in  different  retinoblastoma  cell  lines  com-
pared to the healthy human retina. Changes in endo-
genous BMP4 expression itself, in the expression of 
BMP4  pathway  molecules  and/or  loss  or  reduced 
levels  of  BMPRs  might  provide  an  additional  me-
chanism  through  which  retinoblastoma  cells  escape 
f r o m   a p o p t o s i s   a n d   c e l l   c y c l e  control.  On  the  other 
hand, if expression levels of all signalling components 
a r e   n o r m a l   a n d   B M P R s   a r e   s t i l l   e x p r e s s e d   i n   r e t i n o b-
l a s t o m a   c e l l s ,   d i f f e r e n c e s   i n   r e s p o n s e   t o   B M P 4   c o m-
pared  to  other  cancer  cell  lines  investigated  so  far 
could reflect the role o f   t h e   S m a d   p a t h w a y   i n   t h e   a b-
sence of functional pRb. 
Materials and Methods 
Collection of tissue and preparation of human 
retina 
All  investigations  followed  the  tenets  of  the 
Declaration  of  Helsinki  and  were  approved  by  the 
institutional  human  experimentation  committee. 
Human  retinas  were  obtained  post-mortem  from 
cornea  donors.  Consent  for  donation  and  research 
w a s   g i v e n   b y   t h e   f a m i l y   a n d   c o n f i d e n t i a l i t y   w a s  
maintained. After removal of the cornea, the remain-
d e r   o f   t h e   e y e   w a s   s t o r e d   i n   a   m o i s t  sterile container at 
4°C until further use. Donor tissues were harvested 
within 12 – 4 8   h r s .   D o n o r s   r a n g e d   i n   a g e   f r o m   2 0   y e a r s  
o l d   t o   8 5 ,   w i t h   m o s t   b e i n g   o v e r   5 0   y e a r s   o l d .   A  
c i r c u m f e r e n t i a l   i n c i s i o n   w a s   m a d e   i n   t h e   s c l e r a   o f   t h e  
globes approximately 6 mm   b e h i n d   t h e   l i m b u s .   T h e  
posterior  segment,  including  the  vitreous,  retina, 
choroid, and posterior sclera, was placed in a Petri 
dish. The vitreous was excised under a dissecting mi-
c r o s c o p e .   T h e   r e t i n a   w a s   c a r e f u l l y   s e p a r a t e d   f r o m   t h e  
retinal pigment epithe l i u m   a n d   e x c i s e d   f r o m   t h e   p o s-
t e r i o r   s e g m e n t   a n d   w a s h e d   i n   0 . 1   M   p h o s p h a t e   b u f f e r  
(pH 7.4). Freshly excised retinas were either immedi-
ately frozen in liquid nitrogen or fixed in 4% para-
f o r m a l d e h y d e   i n   0 . 1   M   p h o s p h a t e   b u f f e r   ( p H   7 . 4 )  
overnight at 4°C for immunocytochemistry. 
Cell culture 
We  investigated  8  retinoblastoma  cell  lines: 
WERI-Rb1 [41], Y-79 [42], RBL-1 3 ,   R B L -15, RBL-30, RB 
247C3, RB 355 and RB 383 [43]. Cell lines were culti-
vated  in  Dulbecco`s  modified  Eagles  medium 
( D M E M ;   S i g m a )   w i t h   1 0 %   f e t a l   c a lf  serum  (FCS; 
Cave), 100 U/ml penicillin (Invitrogen), 100 µg/ml 
streptomycin (Invitrogen), 4mM L-glutamine (Sigma), 
50 µM ethandiol (Sigma) and 10 µg/ml insulin (Sig-
ma) at 37°C, 10% CO2 and 80% humidity.  
Cells were treated with different concentrations 
o f   r e c o m b i n a n t   h u m a n   B M P 4   ( R & D   S y s t e m s ,   W i e s-
baden,  Germany)  diluted  from  a  100ng/µl  stock 
s o l v e d   i n   0 . 1 %   B S A   i n   4 m M   H C l   f o r   d i f f e r e n t   t i m e  
spans as indicated in the figures and figure legends. If 
WERI-R b 1   c e l l s   w e r e   t r e a t e d   w i t h   B M P 4   f o r   m o r e  
than 24 hrs, the medium – containing 10% FCS – was 
n o t   c h a n g e d .   F o r   d e t e c t i o n   o f   c e l l   p r o l i f e r a t i o n ,   5   µ M  
BrDU (Sigma) was added 6h before end of the culture. 
DNA and protein were as extracted from these cell 
l i n e s   u s i n g   t h e   p r o t o c o l s   d e s c r i b e d   b e l o w .   F o r   i m-
munocytochemistry,  cells  were  seeded  on 
Poly-D-lysine  coated  (Sigma)  coverslips  and  fixed 
w i t h   i c e   c o l d   a c e t o n e   f o r   1 0   m i n   o r   c o l d   4 %   p a r a f o r-
maldehyde for 1h.  Int. J. Biol. Sci. 2010, 6 
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Semiquantitative RT-PCR assay 
Retinas  and  cells  were  homogenized  in  1  ml 
Trizol (Invitrogen) by manual disruption with an au-
t o c l a v e d   p l a s t i c   p e s t l e   a n d   p a s s i n g   t h e   t i s s u e   o r   c e l l s ,  
respectively through a 25G needle with a 1ml insulin 
syringe  several  times.  The  RNA  was  extracted  ac-
cording  to  the  manufacturer’s  instructions  (Invitro-
g e n ) .   E q u a l   a m o u n t s   o f   R N A   w e r e   subjected  to  an 
RT-reaction  using  oligo(dt)20  primers  (Invitrogen), 
employing  the  SuperScript  III  reverse  transcriptase 
system (Invitrogen) and following the manufacturer`s 
instructions. An additional DNase I (Invitrogen) di-
gestion  was  performed  in  advance  to  avoid  cross 
contamination  with  genomic  DNA.  1.5  µl  of  the 
RT-r e a c t i o n   p r o d u c t   w e r e   t a k e n   f o r   P C R   w i t h  
BMPR-IA,  BMPR-IB,  BMPR-II  and  GAPDH  (Glyce-
raldehyde-3-phosphate  dehydrogenase)  specific  pri-
mers  already  published  [37]  BMPR-IA_for: 
5`-TAAGGTGACAGTACACAGGAACA-3`,  BMPR- 
IA_rev:  5`-TCTATGATGGCAAAGCAATGTCC-3` 
(amplicon:  298  bp;  Tm.  55°C);  BMPR-IB_for: 
5`-GTTGTAAATGCCACCACCATT-3`;  BMPR-IB_rev 
5`-GTCTGGTTTCTTGTCTTTTAT-3`  (amplicon:  378 
b p ;   T m   :   5 8 ° C ) ;   B M P R -II_for:  5`-TCCTCTCATCAG 
CCATTTGTCCTTC-3`;  BMPR-II_rev:  5`-AGTTACT 
ACACATTCTTCATAG-3 `   ( a m p l i c o n :   4 5 7   b p ;   T m  
55°C); Id1_for 5´- CGGATCTGAGGGAGAACAAG - 
3´;  Id1_rev  5´-  TGAGAAGCACCAAACGTGAC  -  3´ 
(amplicon:  211bp;  Tm  59°C);  Id2_for  5´- 
CGTGAGGTCCGTTAGGAAAA  -  3´;  Id2_rev  5´- 
ATAGTGGGATGCGAGTCCAG  -  3´  (amplicon:  237 
bp;  Tm  60°C);  Smad7_for  5´-  AGCAGGCCAC 
ACTTCAAACT  –  3´;  Smad7  _rev  5´- 
GTGTCCTGCCGATCATACCT  –  3´  (amplicon:  219 
b p ;   T m   5 9 ° C ) ;   G A P D H for  5`-CATCACCATCTTG 
GAGC-3`;  GAPDHrev  5`-ATGACCTTGCCCACAG 
CCTT-3 `   ( a m p l i c o n :   3 8 4   b p   T m   2 0 ° C ;   I n v i t r o g e n ) .   P C R  
products w e r e   a m p l i f i e d   u s i n g   a n   e x p a n d   h i g h   f i d e l-
ity Taq polymerase (Roche) and employing the fol-
l o w i n g   c o n d i t i o n s :   ( i )   5   m i n   a t   9 4 ° C ;   ( i i )   3 5   t o   3 7   a m-
plification cycles (for GAPDH: 27 cycles); 1 min at 
94°C, 1 min at 55°C (or 58°C), 30 sec at 72°C; (ii) 5 min 
at 7 2 ° C .   T h e   P C R   p r o d u c t s   w e r e   s e p a r a t e d   o n   a   2 %  
agarose gel and stained with ethidium bromide.  
Quantitative Real-time PCR 
Quantitative real time PCR analyses were per-
formed using a 7300 Real-Time PCR System (Applied 
B i o s y s t e m s ) .   T h e   f o l l o w i n g   T a q m a n   G e n e   E x pression 
Assays  (Applied  Biosystems)  were  used:  Id1:  ID 
Hs00357821_g1;  Id2:  ID  Hs00747379_m1;  Id3:  ID 
Hs00171409_m1; p21 (CDKN1A): ID Hs99999142_m1; 
p27:  ID  Hs00153277_m1;  p53:  ID  Hs00153340_m1; 
p130: ID Hs00180562_m1; p107: ID Hs00765707_m1; 
BMP4:  ID  Hs00181626_m1.  GAPDH  (ID 
Hs99999905_m1) was used as an endogenous control. 
R e a l   t i m e   P C R   r e a c t i o n s   w e r e   p e r f o r m e d   i n   d u p l i c a t e  
a n d   a   t o t a l   v o l u m e   o f   2 0   µ l   w a s   a p p l i e d   t o   t h e   f o l-
lowing  program: 2  minutes 50°C, 10 minutes 95°C 
f o l l o w e d   b y   4 0   c y c l e s   o f   1 5   s e c o n d s   95°C  and  60 
seconds 60°C. Relative quantification was calculated 
by the 7300 Real-Time PCR System software (Applied 
Biosystems). Results represent mean values of at least 
three independent experiments. 
Antibodies 
For detection of BMPR-IA and BMPR-I B   w e   u s ed 
rabbit  polyclonal  BMPR-IA  (H-60;  Santa  Cruz, 
sc-20736) and BMPR-IB (H-44; Santa Cruz, sc-25455) 
antibodies  raised  against  amino  acids  24-83  of 
BMPR-IA  and  15-58  of  BMPR-I B   o f   h u m a n   o r i g i n ,  
respectively. BMPR-I I   w a s   d e t e c t e d   b y   a   p o l y c l o n a l  
BMPR-II  (R&D, AF811) antibody  produced in goats 
immunized with purified, NS0-derived, recombinant 
human BMPR-II extracellular domain. PC-3 cell lysate 
(Santa Cruz, sc-2220)  was  used  as  positive  controls. 
For Smad translocation studies, a mouse monoclonal 
smad1 antibody (A-4; Santa Cruz; sc-7965) was used. 
For pathway studies, the following antibodies were 
u s e d :   a   m o u s e   m o n o c l o n a l   p 2 1 Waf1/Cip1 (DCS60) anti-
body (Cell Signaling #2946),, a rabbit polyclonal Bax 
antibody (Cell Signaling #2772), a rabbit polyclonal 
P-Smad1/5/8  antibody  (Cell  Signaling  #9511).  For 
B r d U   i m m u n o c y t o c h e m i s t r y   a   r a t   a n t i -BrDU antibody 
(Abcam; BU1/75 (ICR1); ab6326) was used. 
Western blot analysis   
For Western blot analysis, retinas and cells were 
homogenized in modified Ripa buffer (0.5% sodium 
deoxy c h o l a t e   /   0 . 1 %   S D S   i n   P B S )   o r   I P N 150 buffer (50 
m M   T r i s H c l   /   1 5 0   m M   N a C l   /   5   m M   M g C l 2 / 0.1% 
NP40 / 1mM DTT / 0.1M NaVan / 0.1 M PMSF / 1M 
N a F   /   c o m p l e t e   p r o t e a s e   i n h i b i t o r   c o c k t a i l ) ,   r e s p e c-
tively. The extracts were fractionated in a 7.5 - 12% 
SDS-PAGE  and transferred to a nitrocellulose mem-
b r a n e   b y   t a n k   b l o t t i n g   w i t h   2 5   m M   T r i s / H C l ,   p H   8 . 7 ,  
192  mM  glycine,  10%  methanol  as  transfer  buffer. 
Membranes were blocked in phosphate buffer saline 
( P B S ;   p H   7 . 4 )   w i t h   0 . 1 %   T w e e n -20  (PBS-T)  and  5% 
bovine serum albumin (BSA) at 4°C overnight or for 
3 0   m i n   a t   r o o m   t e m p e r a t u r e .   F o r   t h e   d e t e c t i o n   o f  
BMPRs the membranes were incubated with the rab-
bit polyclonal BMPR-IA (1:100), the goat polyclonal 
BMPR-IB  (1:500)  and  the  goat  polyclonal  BMPR-II 
(1:200)  primary  antibodies  in  3%  milk  powd-
er/PBS/0.05%  Tween-20  (BMPR-I A   a n d   B )   o r   3 %  
BSA/PBS/0.05% Tween-20  (BMPR-I I )   f o r   2   h o u r s   a t  
room  temperature.  For  the  detection  of  p21,  Bax, Int. J. Biol. Sci. 2010, 6 
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P-Smad1/5/8,  and  Smad1  membranes  were  incu-
bated with the primary antibodies (all 1:1000) in 5% 
milk powder/TBS/0.1%  Tween-20 or TBS-T  (Tris  / 
NaCl / Tween-20) / 0.02% NaN3 / 0.025% BSA at 4°C 
with  gentle  shaking  overnight.  After  three  washes 
w i t h   T B S ,   t h e   m e m b r a n e s   w e r e   i n c u b a t e d   f o r   1 h   a t  
room temperature with the respective secondary an-
tibody  (horseradish   p e r o x i d a s e   ( H R P ) -conjugated 
anti-rabbit and anti-goat IgG (DAKO, Germany) at a 
dilution  of  1:1500  (anti-rabbit  HRP)  –  1:10,000  (an-
ti-g o a t   H R P )   i n   2 %   m i l k   p o w d e r / P B S / 0 . 0 5 %  
Tween-20. Signals were developed by the SuperSignal 
West  Pico  Chemiluminescent  Substrate  (Pierce)  and 
visualized  in  a  chemiluminescence  imager  (Chemi 
G e n i u s ,   B i o   I m a g i n g   S y s t e m s ,   S y n g e n e ) .   D e n s i t o m e-
t r i c   m e a s u r e m e n t s   w e r e   p e r f o r m e d   b y   q u a n t i f y i n g   t h e  
d e n s i t y   o f   t h e   b a n d s   vs the local background using Bio 
Imaging  System  software  (Syngene).  Depending  on 
the origin of primary antibody (rabbit vs goat), blots 
were re-s t a i n e d   w i t h   a   g o a t   p o l y c l o n a l   a n t i -actin an-
tibody  (I-19; Santa Cruz, sc-1616, 1:500) or a mouse 
monoclonal  antibody  to  GAPDH  (6C5;  Abcam, 
ab8245, 1:1000) to verify equal protein loading in all 
lanes. 
Immunocytochemistry 
Immunostaining was performed using the same 
antibodies used for immunoblots. After a 1h blocking 
s t e p   w i t h   1 0   %   n o r m a l   g o a t   s e r u m   ( N G S ;   f o r   B M P R -IA 
and  B)  or 10%  bovine  serum  albumin in  phosphate 
buffer  saline  (PBS;   p H   7 . 4 ;   f o r   B M P R -II), 
ten-micrometer cryo-s e c t i o n s   o f   h u m a n   r e t i n a s   o r   r e-
t i n o b l a s t o m a   c e l l s   s e e d e d   a n d   f i x e d   o n   c o v e r s l i p s  
w e r e   i n c u b a t e d   w i t h   t h e   p r i m a r y   a n t i b o d i e s   a t   a   d i l u-
tion  of  1:200  (BMPR-I A   a n d   B )   o r   1 : 1 0 0   ( B M P R -II), 
respectively. For detection of   g a n g l i o n   c e l l s   t h e   s e c-
t i o n s   w e r e   d o u b l e   s t a i n e d   w i t h   t h e   g a n g l i o n  
cell-specific,  nuclear  marker  Brn3a  (Chemicon; 
MAB1585; 1:100). Following 1h permeabilisation with 
3   m g / m l   B S A / 1 0 0   m M   g l y c i n e / 0 . 2 5 %   t r i t o n   X -100, 
endogenous biotin was blocked using a biotin block-
ing  kit  (DAKO).  After  overnight  incubation  at  4°C 
w i t h   t h e   r e s p e c t i v e   m a k e r s ,   t h e   r e a c t i o n   w a s   v i s u a-
l i z e d   u s i n g   t h e   r e s p e c t i v e   b i o t i n y l a t e d   I g G s   ( 1 : 2 0 0 )  
and  streptavidin-conjugated Cy3 or FITC secondary 
antibodies (MoBiTec) at a dilution of 1:800. Sections 
w e r e   a n a l y z e d   w i t h   a   N I K O N   E c l i p s e   E 6 0 0   m i c r o-
scope equipped with epifluorescence, a NIKON CCD 
camera and NIKON Eclipsenet software. As controls, 
i n   a l l   c a s e s   P B S   w a s   s u b s t i t u t e d   f o r   t h e   p r i m a r y   a n t i-
sera in order to test for nonspecific labeling. No  spe-
cific cellular staining was observed when the primary 
antiserum was omitted.  
For  BrdU  immunocytochemistry,  cells  were 
p e r m e a b i l i s e d   i n   1 %   t r i t o n   X -100 for 30 min. To de-
n a t u r e   t h e   D N A ,   c e l l s   w e r e   i n c u b a t e d   i n   2 N   H C l   a t  
3 7 ° C   f o r   6 0   m i n .   T h e   H C l   w a s   n e u tralized  with  so-
d i u m   b o r a t e   a n d   u n s p e c i f i c   s t a i n i n g   w a s   b l o c k e d   b y  
1 h   i n c u b a t i o n   i n   P B S   /   0 . 3 %   t r i t o n   X -100 / 4% BSA / 
5 %   N G S .   C e l l s   w e r e   i n c u b a t e d   w i t h   t h e   B r D U   a n t i-
b o d y   d i l u t e d   1 : 1 0 0 0   i n   P B S   /   0 . 1 %   t r i t o n   /   4 %   B S A   /  
1 %   N G S   a t   4 ° C   o v e r n i g h t   a n d   t h e   r e a c t i on was visua-
lized with an goat anti rat FITC (1:1000) antibody. For 
immunolocalisation of Smad 1, cells were permeabi-
lised in 100% cold MeOH for 5 min on ice, washed 3 
t i m e s   i n   P B S ,   b l o c k e d   i n   P B S   /   0 . 3 %   t r i t o n   X -100 / 4% 
B S A   /   5 %   n o r m a l   g o a t   s e r u m   ( N G S )   f or 1h at room 
temperature and incubated with the SMad1 antibody 
diluted 1:200 in PBS /0.1 triton X-100 / 4% BSA / 1% 
NGS at 4°C overnight. 
Cell cycle analysis 
For cell cycle analysis by FACS, cells suspended 
in Deitch buffer (10 mM Tris-hydrochloride (pH 7.5) / 
5 mM MgCl2)   a n d   s t a i n e d   w i t h   1 0 0   µ g / m l   p r o p i d i u m  
iodide44 w e r e   a n a l y z e d   i n   a   C o u l t e r   E P I C S   X L   f l o w  
c y t o m e t e r   u s i n g   S Y S T E M   I I   V e r s i o n   3 . 0   s o f t w a r e  
(Beckman-Coulter,  Krefeld,  Germany).  The  percen-
tage of cells present in the sub-G1 peak, representing 
apo p t o t i c   c e l l s ,   w a s   c a l c u l a t e d   a f t e r   e x c l u s i o n   o f   c e l l  
d o u b l e t s .   T h e   s u m   o f   c e l l s   i n   G 2   a n d   S   p h a s e   w a s   d e-
fined as the percentage of proliferating cells. Alterna-
tively,  proliferating  cells  and  pyknotic  nuclei  were 
counted  manually  from  BrdU-  and 
4',6-Diamidino-2-phenylindole  (DAPI)-stained  cells 
on  coverslips,  respectively.  For  this  purpose,  in  a 
survey, at least 10 different sections of one coverslip 
and at least 1000 cells were counted and the number 
o f   a p o p t o t i c ,   c l e a r l y   p y k n o t i c   n u c l e i   ( a t   l e a s t   1 0 )   o r  
clearly BrDU-positive stained cells was determined. 
Inhibition of endogenous caspase activity 
In  order  to  block  endogenous  caspase  activity, 
Boc-D-fmk (Merck, Germany), a broad spectrum cas-
pase inhibitor was used. WERI-Rb1 cells were seeded 
on Poly-D-lysine c o a t e d   c o v e r s l i p s   a n d   p r e -incubated 
i n   3 8 µ M   B o c -D-fmk for 30 min. Afterwards cells were 
i n c u b a t e d   f o r   2 4 h   i n   D M E M   s u p p l e m e n t e d   w i t h   4 0 n M  
recombinant human BMP4 or BMP4 together with the 
c a s p a s e   i n h i b i t o r .   T h e   n u m b e r   o f   p y k n o t i c   n u c l e i   w a s  
assed by DAPI cell counts. 
Results 
Expression of BMPR subtypes in the human re-
tina 
R N A   w a s   i s o l a t e d   f r o m   p o o l e d   h u m a n   r e t i n a s   o f  
5   c o r n e a   d o n o r s   a n d   c D N A   w a s   a m p l i f i e d   b y   t h e   u s e  Int. J. Biol. Sci. 2010, 6 
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o f   s p e c i f i c   p r i m e r s ,   t e s t i n g   f o r   B M P R -IA, BMPR-IB, or 
BMPR-II transcripts (Fig. 1A). Amplification products 
f o r   a l l   t h r e e   B M P R   s u b t y p e s   w e r e   c l e a r l y   v i s i b l e   a f t e r  
separation in an agarose gel. The cellular localization 
o f   B M P R s   i n   t h e   h u m a n   r e t i n a   w a s   r e v e a l e d   i n   c r y o-
sections, stained with specific antibodies for the dif-
ferent  receptor  subtypes.  Double  labeling  studies 
with  the  established  ganglion  cell  marker  Brn3  re-
v e a l e d   t h a t   a l l   B M P R   s u b t y p e s   a r e   e x p r e s s e d   o n   t h e  
surface of ganglion cells (Fig. 1C-G). No specific labe-
l i n g   f o r   B M P R I A ,   B M P R I B ,   o r   B M P R I I   w a s   d e t e c t e d  
in the photoreceptor layer or the inner nuclear layer. 
Immunocytochemical detection of BMPRs on 
retinoblastoma cells 
Immunocytochemical labeling of WERI-Rb1 and 
Y-7 9   c e l l s   w i t h   s p e c i f i c   a n t i b o d i e s   f o r   t h e   t h r e e   B M P R  
subtypes BMPR-IA (Fig. 1H,I), BMPR-IB  (Fig. 1J,K) 
and  BMPR-II (Fig. 1L,M) revealed the expression of 
a l l   B M P R s   o n   t h e   s u r f a c e   o f   t h e s e   w e l l   c h a r a c t e r i z e d  
and frequently used retinoblastoma cell lines. 
 
 
 
 
 
 
 
 
Figure 1. Detection of BMPRs in the human retina (A-G) 
and retinoblastoma cell lines (H-M) by reverse transcrip-
tion-polymerase chain reaction (RT-PCR;  A)   a n d   i m m u-
nohistochemistry (B-M) .   ( A) PCR amplification products of 
the expected sizes were detected for each BMPR subtype. 
For orientation, the size of the products is indicated to the 
right  and  the  prominent  600  bp   l i n e   o f   a   1 0 0 -bp  DNA 
marker is indicated to the left. (B-G) Immunohistochemical 
detection of BMPR-IA, BMPR-IB, and BMPR-II in cryosec-
tions of the human retina. Immunohistochemical double 
labeling studies with the established ganglion cell marker 
Brn3a revealed that BMPR-IA is localized on the surface of 
ganglion cells (B,C). The same holds true for the BMPR-IB 
(D,E)   a n d   t h e   B M P R I I   ( F,G). The white insets in B,D,F are 
shown in higher magnification in C,E,G, respectively. Ab-
breviations: GCL, ganglion cell layer; INL, inner nuclear 
layer; ONL, outer nuclear layer. Scale bar in (B) = 50 µm 
a l s o   a p p l i e s   f o r   D , F ;   S c a l e   b a r   i n   ( C)   =   2 0   µ m   a l s o   a p p l i e s   t o  
E,G. (H-M) Immunocytochemical labelling of BMPR sub-
types in the retinoblastoma cell line WERI-Rb-1   ( H,J,L)   a n d  
Y-79 (I,K,M). Scale bar in (H) = 20 µm also applies to I-M. 
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Transcripts for BMPRs in retinoblastoma cell 
lines 
RT-P C R   a n a l y s i s   f o r   B M P R   t r a n s c r i p t s   i n   8   r e t i-
noblastoma cell lines confirmed that all BMPR sub-
types  are  expressed  in  these  cells  (Fig.  2). 
Semi-quantification of the RT-PCR data showed that 
the levels of BMPR-IA  (Fig.  2A),  BMPR-IB  (Fig.  2C) 
and BMPR-II (Fig. 2E) transcripts are not significantly 
reduced in retinoblastoma cell lines compared to the 
h e a l t h y   h u m a n   r e t i n a   c o n t r o l s ,   e x c e p t   f o r   t h e   l evel of 
BMPR-IB in RBL-13 cells.  
 
 
 
Figure 2.  Comparison of BMPR-IA, BMPR-IB, and BMPR-II mRNA (A,C,E)   a n d   p r o t e i n   ( B,D,F) expression levels in 
healthy human retina (ctr.) and eight retinoblastoma cells lines using reverse transcription-polymerase chain reaction 
(RT-PCR) and Western Blot analysis. The integrity of the cDNA was tested by amplification of the GAPDH transcript. 
Depending on the origin of the primary antibodies (α-rabbit BMPRIA; α-goat BMPRIB and BMPRII), either α-goat actin or 
α-mouse GAPDH were used as housekeeping enzymes to normalize equal protein loading. Quantification of the RT-PCR 
data revealed that the level of BMPR-I A   ( A) ,   B M P R -I B   ( C)   a n d   B M P R -II (E) transcripts in retinoblastoma cell lines resembles 
the mRNA levels found in the healthy human retina control (ctr.), except for the level of BMPR-IB in RBL-13 cells. Quan-
tification of the Western Blot data confirmed the presence of BMPR-IA (B), BMPR-IB (D), and BMPR-II (F) protein in the 
healthy human retina and all retinoblastoma cells investigated. Values are means of three independent experiments (n=3) ± 
s.e.m. * P<0.05; statistical differences compared to basal group, calculated by one way Anova test and Newman-Keuls Post 
test comparing all experimental groups.  Int. J. Biol. Sci. 2010, 6 
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Expression of BMPRIA, BMPRIB, and BMPRII in 
retinoblastoma cells 
Western Blot analysis of BMPR expression in re-
tinoblastoma cell lines confirmed their presence on 
protein level, revealing equal expression of BMPR-IA 
(Fig.  2B),  BMPR-I B   ( F i g .   2 D ) ,   a n d   B M P R I I   ( F i g .   2 F )  
protein  in  the  healthy  human  retina  control  and all 
retinoblastoma cell lines (Fig. 2).  
Expression level of endogenous BMP4 in reti-
noblastoma cells 
As overexpression of BMP4 has been reported 
for different cancer cell lines, changes in BMP4 levels 
might provide a mechanism through which retinob-
lastoma  cells  escape  from  apoptosis  and  cell  cycle 
control,  we  investigated  endogenous  BMP4  expres-
s i o n   b y   r e a l -time  PCR.  Figure  3 summarizes  the  re-
sults  of  three  independent  PCRs,  revealing  that  no 
endogenous BMP4 expression was detectable in 5 out 
of 8 retinoblastoma cell lines investigated. Only RB 
355,  RB  30,  and  RB  383  cells  express  endogenous 
BMP4 at detectable levels, which are, however, sig-
nificantly low e r   c o m p a r e d   t o   t h e   n o r m a l   h u m a n   r e t i-
na, used as a positive control. 
 
 
Figure 3. Endogenous expression of BMP4 in retinoblas-
t o m a   c e l l   l i n e s .   T h e   e x p r e s s i o n   o f   B M P 4   m R N A   w a s   a n a-
lyzed  by  real-time PCR in the retinoblastoma cell lines 
RBL-13,  RBL-15,  RBL-30,  RB  247C3,  RB  355,  RB  383, 
WERI-Rb1, and Y-79. Only RBL-30, RB 355 and RB 383 
expressed BMP4 at detectable levels. Normal human retina 
m R N A   w a s   u s e d   a s   a   p o s i t i v e   c o n t r o l   ( c t r . ) ,   a n d   i t s   e x-
p r e s s i o n   l e v e l   w a s   s e t   a s   1 .   V a l u e s   a r e   m e a n s   o f   t h r e e   i n-
dependent experiments (n=3). 
 
Effects of exogenous BMP4 application on 
apoptosis and cell proliferation of WERI-Rb1 
cells 
In  dose-response  experiments,  WERI-Rb1  cells 
were treated with different concentrations of recom-
b i n a n t   h u m a n   B M P 4   ( F i g .   4 )   t o   t e s t   i t s   e f f e c t   o n  reti-
noblastoma cell apoptosis and proliferation. Apopto-
sis  and  cell  proliferation  levels  were  quantified  by 
flow-cytometric  analysis  (Fig.  4A,C)  and  manual 
counts of DAPI and BrDU stained cells (Fig. 4B,D). No 
pro-apoptotic  effect  could  be  detected  for  exogen-
o u s l y   a p p l i e d   B M P 4   a t   c o n c e n t r a t i o n s   l o w e r   t h a n  
40ng/ml (2, 5, 10, 20ng/ml). At a concentration of 
40ng/ml, BMP4 treatment results in a significant in-
c r e a s e   i n   t h e   n u m b e r   o f   p y k n o t i c   c e l l s .   H i g h e r   c o n-
centrations (80 and 100ng/ml) of recombinant BMP4 
cou l d   n o t   f u r t h e r   i n c r e a s e   t h i s   p r o -apoptotic  effect 
(Fig.  4A).  Application  of  40ng/ml  recombinant  hu-
m a n   B M P 4   r e s u l t e d   i n   a   d o u b l i n g   i n   t h e   n u m b e r   o f  
DAPI-stained, apoptotic cells after 24hrs, 48hrs and 
72hrs  (Fig.  4B).  No  effects  of  BMP4  administration 
upon WERI-Rb1 cell proliferation could be detected 
irrespective  of  the  concentration  (Fig.  4C)  and  the 
culture time (Fig. 4D). 
Transmission of BMP signaling 
 BMP actions on cell proliferation and apoptosis 
are  normally  mediated  by  Smad  proteins.  As 
WERI-Rb1  cells  lack  functional  pRb,  which  is  nor-
mally activated by the Smad pathway, we checked for 
a correct transmission of BMP4 signals in these cells. 
BMP4  treatment  induced  a  significant  up-regulation 
of phosphorylated Smad1, Smad5 and Smad8 levels, 
as determined by Western blots with a specific anti-
body,  detecting  all  three  Smads  (Figure  5A).  Phos-
phorylation  of  Smad1/5/8  was  already  detected 
30min after BMP4 administration. Besides, an evident 
translocation of Smad1 into the nucleus was observed 
upon 1h BMP4 trea t m e n t ,   a s   v i s u a l i z e d   b y   i m m u n o-
cytochemical staining (Figure 5B-E ) .   T h u s ,   B M P 4   s i g-
nals  are  still  transmitted  correctly  to  the  nucleus  in 
WERI-Rb-1   c e l l s .   T h e   d o t t e d   S m a d 1   s t a i n i n g   i n   t h e  
c o n t r o l   g r o u p s   ( F i g u r e   5   B , D )   a p p e a r s   t o   s h o w   d i s-
crete localization in the cytoplasm. If there, however, 
was a correspondence to organelles of the cytoplasm, 
the  staining  pattern  should  disappear  when  Smad1 
translocates  to  the  nucleus,  but  Smad1  staining  re-
mains punctate in BMP4 treated cells (Figure 5C,E). 
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Figure  4. Effect of recombinant human BMP4 on the number of apoptotic (A,B;E,F)  and  proliferating  (C,D;G,H) 
WERI-Rb1 cells. Data gained from FACS analyses after 24 hrs (A,C), manual DAPI (B) and BrDU cell counts (D) after 24, 
4 8   a n d   7 2 h r s ,   a s   i n d i c a t e d   a n d   D A P I   s t a i n s   o n   c o v e r s l i p s   a f t e r   2 4 h   ( E,F). Cells that were only treated with 0.1% BSA in 4mM Int. J. Biol. Sci. 2010, 6 
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HCl, the solvent for recombinant human BMP4, were taken as a control (ctr.) group. In dose-response experiments, re-
tinoblastoma cells were treated with different concentrations of recombinant human BMP4. For FACS analysis cells were 
stained with propidium iodide and the percentage of cells present in the sub-G1 peak, representing apoptotic cells, was 
c a l c u l a t e d .   T h e   s u m   o f   c e lls in G2 and S phase was defined as the percentage of proliferating cells. Administration of 40ng/ml 
recombinant BMP4 showed a significant pro-apoptotic effect in FACS analyses (A), inducing a doubling in the number of 
DAPI positive, pyknotic nuclei after 24, 48 and 72hrs (B), also clearly visible in images from DAPI stains of control (E) vs. 
BMP4 treated cells (F). White arrowheads (E,F) demarcate condensed nuclei of apoptic cells; small white arrows indicate 
apoptotic bodies in pyknotic cells. (C,D). FACS   a n d   B r D U   c e l l   c o u n t s   r e v e a l e d   n o   e f f e c t s   o f   B M P 4   a d m i n i s t r a t i o n   o n   c e l l  
proliferation, neither after 24hrs nor after 48 or 72hrs. Values are means of three independent experiments (n=3) ± s.e.m. 
**P<0 . 0 1 ;   * * *   P <0 . 0 0 1   c a l c u l a t e d   b y   o n e   w a y   A n n o v a   t e s t   a n d  Newman-Keuls Post test comparing all experimental groups. 
(G,H) BrDU stains of cells, 24 hrs after BMP4 treatment, resemble those of control (ctr.) groups. 
 
 
 
 
 
 
 
 
 
Figure  5.  Smad  induction  and 
nuclear  translocation  in 
WERI-Rb-1  cells  after  BMP4 
treatment. (A) Western blot with 
a  specific  P-Smad1/5/8  antibody 
demonstrating  a  significant 
up-regulation  of  activated,  pho-
shorylated  Smad1/5/8  already 
30min after addition of recombi-
nant  BMP4.  Total  Smad1  levels 
served as an internal control and 
remained  constant.  (B-E)  Immu-
nocytochemical  staining  of  cells 
cultured for 1h in the presence of 
40ng/ml  recombinant  BMP4  re-
vealed  that  BMP4  treatment  re-
sults in a significant translocation 
of Smad 1 into the nucleus (C,E), 
whereas  the  Smad  staining  is 
mainly cytoplasmic in the control 
(ctr.)  group,  only  treated  with 
0 . 1 %   B S A   i n   4 m M   H C l ,   t h e   s o l v e n t  
for  recombinant  human  BMP4 
( B , D ) .   A r r o w h e a d s   p o i n t   t o   c y-
toplasmic  Smad  staining.  Arrows 
demarcate Smad translocation to 
the nucleus. Scale bar in (B)   =   5 0  
µm also applies for C-E 
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Involvement of caspases and Bax in BMP4 me-
diated apoptosis 
We  studied  the  involvement  of  caspases,  the 
m a j o r   c e l l   d e a t h   e x e c u t i o n e r s ,   i n   t h e   e x e c u t i o n   o f   c e l l  
death  in  WERI-RB-1  cells.  We  determined  that  in 
WERI-RB-1  cells  endogenous  apoptosis  is  caspase 
independent since the number of pycnotic nuclei was 
n o t   s i g n i f i c a n t l y   r e d u c e d   i n   c e l l s   t r e a t e d   f o r   2 4   h r s  
with Boc-D-fmk, a broad spectrum caspase inhibitor 
( F i g .   6 A ) .   B M P 4   m e d i a t e d   c e l l   d e a t h   i s   a t   l e a s t   p a r-
tially caspase-dependent, as the number of pycnotic 
nuclei  is  marginally,  but  significantly  lower  after 
BMP4/BOC-D-fmk-inhibitor  double  treatment  com-
p a r e d   t o   B M P 4   t r e a t m e n t   a l o n e   ( F i g .   6 A ) .   T h e   p r e d o-
m i n a n t   p a r t   o f   B M P 4   m e d i a t e d   a p o p t o s i s   i n  
WERI-RB1 cells is, however, caspase independent and 
accordingly, levels of activated caspases appeared to 
be too low to be detected by Western Blot analyses, 
where we were not able to detect cleaved caspase-3, 
cleaved  caspase-9,  or  cleaved  caspase-8  although 
WERI-RB-1 cells express high levels of the respective 
pro-caspases (data not shown). 
Pro-apoptotic  Bcl-2 family members have been 
shown to be involved in the signaling of BMPs. Levels 
o f   t h e   p r o -apoptotic  protein  Bax  remain,  however, 
unchanged after BMP4 treatment (Fig. 6B),  
Expression levels of Id1, Id2 and Smad7 in reti-
noblastoma cells 
O n e   r e a s o n   f o r   t h e   m i s s i n g   e f f e c t   o f   B M P 4  
t r e a t m e n t   o n   c e l l   p r o l i f e r a t i o n   c o u l d   b e   t h a t   I d   p r o-
teins  or  the inhibitory Smad7  protein are  constantly 
up-regulated in retinoblastoma cells. RT-PCR analysis 
f o r   B M P R   t r a n s c r i p t s   r e v e a l e d ,   h o w e v e r ,   t h a t   c o m-
pared to healthy human retina controls mRNA levels 
for Id1 (Fig. 7A), Id2 (Fig. 7B) and Smad7 (Fig. 7C) are 
not altered in all 8 retinoblastoma cell lines investi-
gated. 
Induction of Id proteins and influence of BMP4 
administration upon p53, p21, p27, p107 and 
p130 expression levels 
It  has  been  reported  that  Id  proteins  become 
concomitantly up-regulated upon BMP4 signaling in 
v a r i o u s   c e l l   l i n e s ,   p r e v e n t i n g   t h e   s u p p r e s s i o n   o f   c e l l  
proliferation [34, 36]. In the present study, we likewise 
f o u n d   m R N A   e x p r e s s i o n   l e v e l s   o f   I d 1 ,   I d 2   a n d   I d 3   t o  
be significantly up-regulated 24hrs after administra-
tion of 40ng/ml recombinant BMP4 (Fig. 8A).  
O n   t h e   o t h e r   h a n d ,   i t   h a s   b e e n   o b s e r v e d   t h a t  
pRb-deficient  hepatocytes  exhibit  elevated  levels  of 
p53 and p21C IP 1and BMPs have been reported to cause 
an up-regulation of the CDK inhibitors p21 and p27 in 
human cancer cell lines [37]. Endogenous levels of the 
cell cycle regulator p53 and p21 are likewise signifi-
cantly elevated in WERI-R b 1   c e l l s   c o m p a r e d   t o   n o r-
mal human retinas (Fig. 8B), but in the present study, 
w e   d i d   n o t   d e t e c t   a n y   i n c r e a s e   i n   p 5 3 ,   p 2 1 ,   a n d   p 2 7  
expression  levels  upon  exogenous  BMP4  treatment 
(Fig. 8C-E ) .   T h e   p R b -related proteins p107 and p130, 
which are still expressed in RB1 deficient WERI-Rb-1 
cells (data not shown), are likewise not induced upon 
administration of recombinant BMP4 (Fig.8F,G). 
 
 
Figure 6. (A) Involvement of caspases in endogenous and BMP4 meditated cell death of WERI-RB-1 cells. Treatment of 
WERI-R B 1   c e l l s   w i t h   B o c -D-f m k ,   a   b r o a d   s p e c t r u m   c a s p a s e   i n h i b i t o r ,   r e v e a l e d   t h a t   e n d o g e n o u s   a p o p t o s i s   i s   c a s p a s e   i n-
dependent, while BMP4 mediated apoptosis in these retinoblastoma cells is at least partially caspase-dependen t .   V a l u e s   a r e  
means of three independent experiments (n=3) ± s.e.m. *** P<0 . 0 0 1   c a l c u l a t e d   b y   o n e   w a y   A n n o v a   t e s t   a n d   N e w m a n -Keuls 
Post test. (B) Western Blot analyses of changes in Bax protein levels following 24hr BMP4 treatment of WERI-Rb1 cells. 
Levels of the pro-apoptotic protein Bax remain unchanged (B). Int. J. Biol. Sci. 2010, 6 
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Figure 7. Comparison of Id1, Id2 and Smad7 mRNA expression levels in healthy human retina (ctr.) and 8 retinoblastoma 
cells lines (RBL-13, RBL-15, RBL-30, RB 247C3, RB 355, RB 383, WERI-Rb1, Y-79) by RT-PCR. Quantification of RT-PCR 
d a t a   f r o m   t h r e e   ( s m a d 7 )   t o   f i v e   ( I d 1 ,   I d 2 )   i n d e p e n d e n t   e x p e r i m e n t s   r e v e a l e d   t h a t   t h e   l e v e l   o f   I d 1   ( A) ,   I d 2   ( B)   a n d   s m a d 7   ( C) 
transcripts in retinoblastoma cell lines resembles the mRNA levels found in the healthy human retina control.  Int. J. Biol. Sci. 2010, 6 
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Figure 8.   I n d u c t i o n   o f   I d 1 -3   ( A), endogenous expression of p21 and p53 (B), and expression of p53 (C) ,   p 2 1   ( D) ,   p 2 7   ( E), 
p107 (F) and p130 (G) upon recombinant BMP4 administration to cell cultures 24hrs after administration of 40ng/ml re-
c o m b i n a n t   B M P 4 .   M e s s e n g e r   R N A   e x p r e s s i o n   l e v e l s   o f   I d 1 ,   I d 2   a n d   I d 3   a r e   s i g n i f i c a n t l y   u p -regulated in WERI-Rb-1   ( A) upon 
a BMP4 administration, whereas no changes in p53, p21, p27, p107 and p130 expression level were detectable (C-G). 
Endogeneous levels of p21 and p53 are, however, elevated in WERI-R b 1   c e l l s   ( B) .   D a t a   w e r e   g a i n e d   f r o m   r e a l -time PCR 
analyses of three independent experiments. Cells that were only treated with 0.1% BSA in 4mM HCl, the solvent for re-
c o m b i n a n t   h u m a n   B M P 4 ,   w e r e   t a k e n   a s   a   c o n t r o l  (ctr.) group for A and C-G,   h e a l t h y   h u m a n   r e t i n a   w a s   u s e d   a s   a   r e f e r e n c e  
in B and the expression level was set as 1, respectively. Int. J. Biol. Sci. 2010, 6 
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Discussion 
The expression of BMPRs has been described for 
the chick and murine retina by our group and others 
[12,14,18,45,46]. We showed recently that BMPRs are 
localized on retinal ganglion cells of the developing 
murine retina [18]. The particular expression of BMPR 
on human retinal ganglion cells observed in the study 
presented here can probabl y   b e   e x p l a i n e d   i n   t e r m s   o f  
B M P   a c t i v i t y   b e i n g   a s s o c i a t e d   w i t h   P C D   a n d   i t s   i n-
volvement in retinal patterning and formation of re-
tinotectal  projections.  We  and  others  demonstrated 
that  BMP4  mediates  apoptotic  cell  death  in  the  de-
veloping chick and murine ret i n a ,   w h e r e   B M P 4   t r i g-
g e r s   g a n g l i o n   c e l l   d e a t h   [ 1 8 , 4 5 , 4 6 ] .   P C D   i s   a   p h y s i o-
logical phenomenon and represents the most common 
m e c h a n i s m   t o   r e g u l a t e   t h e   s i z e   o f   c e l l   p o p u l a t i o n s  
d u r i n g   d e v e l o p m e n t   a s   w e l l   a s   i n   a d u l t   l i f e .   A s   t h e  
retina develops from a single layer of undifferentiated 
neuroectoderm extraneous cells unable to make func-
tional neural connections are eliminated by apoptosis. 
As ganglion cells are the neurons that finally transmit 
t h e   s i g n a l   t o   t h e   b r a i n ,   i t   i s   r e a s o n a b l e   t o   a s s u m e   t h a t  
their number requires an especially tight regulation, 
w h i c h   i s   o b v i o u s l y   m e d i a t e d   b y   B M P 4   s i g n a l i n g .   T h i s  
might  explain  why  especially  ganglion  cells  express 
the  required  receptors.  Besides,  BMPs  have  been 
s h o w n   t o   p l a y   a   k e y   r o l e   i n   d o r s o -ventral patterning 
o f   t h e   r e tina and formation of retinotectal projections 
(for review see: [46]).   I n   t h i s   c o n t e x t ,   i t   h a s   b e e n   r e-
p o r t e d   t h a t   t a r g e t e d   d e l e t i o n   o f   B M P R I B   i n   m i c e   r e-
s u l t e d   i n   f a i l u r e   o f   v e n t r a l   g a n g l i o n   c e l l s   t o   e n t e r   t h e  
optic nerve (for review see: [46]). 
BMP7  expression  had  been  examined  in  the 
adult human retina [46], but until now, BMP receptor 
expression in the human eye was only systematically 
studied in the cornea, conjunctiva and the trabecular 
m e s h w o r k   a n d   o p t i c   n e r v e   h e a d   i n   t h e   c o n t e x t   o f  
glaucoma  [47-50]. Yamada  et  al.  investigated  BMPR 
expression in malignant glioma tumors [31], but to 
o u r   k n o w l e d g e ,   t h e   p r e s e n t   s t u d y   i s   t h e   f i r s t   i n v e s t i-
gating BMPR expression in retinoblastoma cell lines 
and  comparing  expression  levels  of  healthy  retinal 
neurons with those in pathologically altered retinob-
lastoma cells.  
It has been shown that retinoblastoma cells (i.e. 
Y-79 and WERI-R b 1 )   a r e   r e s i s t a n t   t o   T G F -ß  activity 
d u e   t o   t h e   a b s e n c e   o f   T G F -ß   b i n d i n g   [ 2 7 ] .   H o r i e   e t   a l .  
demonstrated  that  Y-79 and WERI-Rb1 retinoblasto-
ma  cell s   d o   n o t   e x p r e s s   T ß R I I   m R N A ,   w h e r e a s   T ß R I  
mRNA  was  detected  [28].  Loss  of  TßRII  represents 
one  mechanism  through  which  retinoblastoma  cells 
e s c a p e   f r o m   g r o w t h   c o n t r o l   [ 2 6 ] .   I t   h a s   b e e n   s h o w n  
t h a t   s o m e   h u m a n   m y e l o m a   c e l l   l i n e s   l a c k   B M P R I A  
and BMPRIB [19]. Thus, one might have speculated 
t h a t   r e t i n o b l a s t o m a   c e l l s   l i k e w i s e   l a c k   B M P R s .   I n   t h e  
present  study  we,  however,  demonstrated  that  all 
BMPR subtypes are expressed on all 8 retinoblastoma 
cell lines investigated, including Y-79 and WERI-Rb1. 
All retinoblastomas develop from the immature retina 
and have mutations of both RB alleles, but it is rea-
sonable to assume that mutations in additional genes 
contribute  to  promotion  and  progression  of  this  tu-
mor. A mutational loss or reduced levels of BMPRs, 
found  in  o t h e r   t u m o r   c e l l s ,   w o u l d   p r o v i d e   a n   a d d i-
tional mechanism through which developing retinal 
cells escape from apoptosis control and form retinob-
lastomas. If the fact that retinoblastoma cells show no 
B M P R   l o s s   b u t   e x h i b i t   f u l l   B M P R   e q u i p m e n t   a n d   a r e  
thus receptive to BMP4 stimuli provides a mechanism 
b y   w h i c h   B M P s   e x c e r t   i n h i b i t o r y   o r   s t i m u l a t o r y   e f-
f e c t s   o n   i n v a s i v e   t u m o r   g r o w t h   n e e d s   t o   b e   d e t e r-
mined. Along this line a positive correlation between 
t h e   m a l i g n a n c y   g r a d e   o f   g l i o m a   a n d   B M P R   e x p r e s s i o n  
has, however, been found as BMPRIB is progressively 
e x p r e s s e d   i n   m a l i g n a n t   g l i o m a   t u m o r s   c o m p a r e d   w i t h  
low-grade astrocytomas and gliosis [31], suggesting 
t h a t   t u m o r   c e l l s   m a y   b e   m o r e   r e s p o n s i v e   t o   t h e   a c t i o n  
of BMPs.  
It has been reported that BMP4 is overexpressed 
in  melanoma  cell  lines  [22].  BMP4  overexpression 
followed by enhanced invasiveness was likewise re-
ported for hepatocellular carcinoma, adenocarcinoma 
and  colorectal  cancer  [23-2 5 ] .   B M P 2   e x p r e s s i o n ,   b y  
contrast, is not prominent in melanomas and was only 
de t e c t e d   i n   t w o   o u t   o f   n i n e   c e l l   l i n e s   a n a l y z e d   [ 2 2 ] .  
Comparable  to  latter  results,  we  could  only  detect 
BMP4 expression in three out of eight retinoblastoma 
cell  lines  in  the  present  study.  As  we  and  others 
d e m o n s t r a t e d   t h a t   B M P 4   i n d u c e s   a p o p t o s i s   i n   n o r m a l 
retinal cells [11,18] and inhibits cell proliferation in 
cancer  cells [20,21],  intrinsic  down-r e g u l a t i o n   o f   e n-
dogenous  BMP4  might  provide  an  additional  me-
chanisms by which retinoblastoma cells escape from 
apoptosis and cell cycle control.  
It is not known   i f   t h e   i m p a i r m e n t   o f   p R b   w o u l d  
a l t e r   t h e   g r o w t h   i n h i b i t o r y   p o t e n t i a l   o f   B M P 4 .   T h u s , 
we  asked  whether  RB1-deficiency  would  affect  res-
ponses  to  BMP4,  which  induces  apoptosis  and  cell 
c y c l e   a r r e s t   i n   o t h e r   c e l l   l i n e s .   I t   h a s   b e e n   s h o w n   t h a t  
BMP4 treatment of tumor cells increased apoptosis in 
OH-2,  IH-1 myeloma cells and undifferentiated hu-
m a n   c a n c e r   c e l l s   [ 2 0 , 3 0 ] .   R e s u l t s   f r o m   o u r   c e l l   c u l t u r e  
experiments  likewise  demonstrate  an  increase  in 
apoptosis  of  WERI-Rb-1  retinoblastoma  cells  after 
BMP4 treatment. While analysing retinoblastoma cell Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
713 
lines, counting DAPI-positive pyknotic nuclei thereby 
provides an objective, reliable, but much more sensi-
tive method evaluating subtle yet statistically highly 
significant apoptotic effects.  
Bcl-2 family members play a critical role in the 
activation of cell death executors [51,52]. Members of 
t h e   B c l -2   f a m i l y   c o m p r i s e   p r o -a p o p t o t i c   ( e . g .   B a x ,   B a k )  
and anti-apoptotic (e.g. Bcl-2, Bcl-XL) proteins. It has 
been reported that BMP4 induces the expression of 
Bax in myeloma and   h y b r i d o m a   c e l l s ,   w h e r e a s   B M P 2  
h a s   n o   e f f e c t s   o n   t h e   e x p r e s s i o n   o f   B a x   [ 5 3 , 5 4 ] .   L a g n a  
e t   a l .   r e p o r t e d ,   h o w e v e r ,   t h a t   B M P 4   m e d i a t e s   a p o p t o-
s i s   o f   p u l m o n a r y   a r t e r y   s m o o t h   m u s c l e   c e l l s   b y   t h e  
activation of caspases, whereby Bax levels remained 
unchanged [55]. Results of our experiments showed 
that BMP4-mediated apoptosis in WERI-Rb-1 cells is 
mainly  caspase  independent  and  accordingly,  Bax 
expression levels remained unchanged. 
BMP4 inhibits proliferation in many cancer cell 
lines,  e.g.  in  multiple  myeloma  cells   a n d   t u-
mor-initiating precursors of glioblastoma cells [20]. In 
o u r   e x p e r i m e n t a l   s e t   u p ,   c e l l   p r o l i f e r a t i o n   w a s ,   h o w-
ever, not affected by BMP4 treatment irrespective of 
t h e   c u l t u r e   t i m e   a n d   c o n c e n t r a t i o n   a n d   o n e   m i g h t  
think of different reasons for this result. 
On the one hand, retinoblastoma cell lines lack 
the  RB1  gene,  but  we  demonstrated  that  the 
pRb-related  proteins  p107  and  p130,  contributing  to 
the  regulation  of  the  same  genes  [56]  are  still  ex-
pressed, at least in WERI-Rb1 cells. Besides, Rivadi-
neira et al. reported that factors other than pRb can 
mediate E2F-dependent down-stream effects to regu-
late  cell  cycle  control  [57].  Sheahan  et  al.  observed 
elevated  levels  of  p21CIP1  and  p53  in  pRb-deficient 
hepatocytes  and  identified  a 
pRb-independent-p53-dependent effector pathway of 
E 2 F   i n h i b i t i o n   i n   t h e s e   c e l l s   [ 5 8 ] .   I n   t h e   p r e s e n t   s t u d y ,  
WERI-Rb1  cells  likewise  exhibited  elevated  endo-
genous levels of p21 CIP1 and p53. In human cancer and 
non-cancer cell lines, BMPs – including BMP4 - have 
been reported to c a u s e   a n   u p -r e g u l a t i o n   o f   p 2 1 CIP1 and 
p27KIP1,   l e a d i n g   t o   c e l l   c y c l e   a r r e s t   [ 3 3 , 3 4 , 5 9 -63].  This 
induction is mediated via the smad signalling path-
way, which, according to our results, is still intact in 
WERI-Rb1  cells.  We,  however,  could  not  detect 
changes in  p21 CIP1, p27KIP1or p53 expression levels in 
RB1 deficient WERI-R b 1   c e l l s   u p o n   e x o g e n o u s   B M P 4  
administration,  presumably  due  to  the  significantly 
elevated  endogenous  levels  in  these  cells  and/or 
concomitant  Id  induction  (see  below).  We  likewise 
did  not  detect  any  BMP4-dependent  regulation  of 
p107 or p130 levels. Thus, in WERI-Rb1 cells pRb loss 
i s   o b v i o u s l y   n o t   c o m p e n s a t e d   f o r   a n d   p r e v e n t s   a n  
anti-p r o l i f e r a t i v e   r e s p o n s e   t o   B M P 4 ,   w h i c h   n o r m a l l y  
induces cell cycle arrest. 
One might also have speculated that inhibitory 
Smad7 protein levels are constantly up-regulated  in 
retinoblastoma cells as it has been shown for various 
cancers.  Smad7  is  overexpressed  in  50%  of  human 
pancreatic cancers and it has been shown that these 
c a n c e r   c e l l s   a r e   r e s i s t a n t   t o   T G F -ß  with  respect  to 
growth inhibition induction [35]. We, however, could 
not  detect  any  changes  in  smad7  expression  levels 
when comparing retinoblastoma cells to healthy hu-
man retina controls. 
On the other hand, it has been reported that Id 
proteins,  known  to  play  a  critical  role  in  cancer 
[ 6 4 , 6 7 ] ,   d e f i n e   t h e   p o t e n c y   o f   c e l l   p r o l i f e r a t i o n   r e s-
p o n s e s   t o   B M P   [ 6 8 ] .  Elevated  levels  of  Id  proteins 
have  been  found  in  tumor  cell  lines  including  neu-
r o b l a s t o m a   c e l l s   [ 6 4 , 6 9 , 7 0 ] .   I n   t h e   p r e s e n t   s t u d y ,   w e  
did not detect elevated endogenous Id levels in any of 
the retinoblastoma cell lines investigated. Id proteins 
become concomitantly up-regulated upon BMP4 sig-
naling, e.g. in endothelial, epithelial and breast cancer 
cells [34,36,71], inhibiting the expression of the CDK 
inhibitor  p21  [72].  BMP7  has  been  shown  to  highly 
i n d u c e   p 2 1   e x p r e s s i o n ,   b u t   d e s p i t e   t h i s ,   B M P 7   o n l y  
weakly suppresses epithelial cell proliferation as Id2 
b e c o m e s   c o n c o m i t a n t l y   i n d u c e d   b y   B M P 7   [ 3 7 ] .   I n   t h e  
p r e s e n t   s t u d y ,   w e   l i k e w i s e   f o u n d   t r a n s c r i p t   l e v e l s   o f  
a l l   t h r e e   I d   i s o f o r m s   t o   b e   s i g n i f i c a n t l y   u p -regulated 
upon  BMP4  administration  in  HER  and  WERI-Rb1 
c e l l s .   T h u s ,   t h e   f a c t   t h a t   i n   o u r   e x p e r i m e n t s   B M P 4  
administration had no effect on cell proliferation in 
the retinoblastoma cell line WERI-Rb1 can be inter-
preted in terms of a compensatory balance between 
high endogenous levels of the CDK inhibitor proteins 
p 5 3   a n d   p 2 1 ,   n o r m a l l y   c a u s i n g   B M P 4 -  induced  cell 
cycle arrest a n d   a   s t r o n g   i n d u c t i o n   o f   p r o -proliferative 
Id proteins. 
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